

ASX Announcement

20 November 2024

## Updated Appendix 3Z

---

Imugene Limited (ASX:IMU) (Imugene or the Company) provides an update to Part 3 of the previously released Appendix 3Z for Dr. Jens Eckstein.

This ASX announcement has been authorised by the Company Secretary.

-END-

For more information please contact:

Leslie Chong  
Managing Director and Chief Executive Officer  
[info@imugene.com](mailto:info@imugene.com)

Investor Enquiries  
[shareholderenquiries@imugene.com](mailto:shareholderenquiries@imugene.com)

Media Enquiries  
Matt Wright  
[matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)

Follow us on Twitter and Instagram @TeamImugene  
Like us on Facebook @Imugene  
Connect with us on LinkedIn @Imugene Limited  
Watch us on YouTube @ImugeneLimited  
Join us on InvestorHub; [IMU.investorhub.com](https://IMU.investorhub.com)

### About Imugene (ASX:IMU)

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. Our unique platform technologies seek to harness the body's immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Our pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug azer-cel



(azercabtagene zapreleucel) which targets CD19 to treat blood cancers. Our pipeline also includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies such as CAR T's for solid tumours. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets.

Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Imugene is well funded and resourced, to deliver on its commercial and clinical milestones. Together with leading specialists and medical professionals, we believe Imugene's immuno-oncology therapies will become foundation treatments for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.

# Appendix 3Z

## Final Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX becomes ASX's property and may be made public.

Introduced 30/9/2001.

<b>Name of entity</b>	Imugene Limited
<b>ABN</b>	99 009 179 551

We (the entity) give ASX the following information under listing rule 3.19.A.3 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of director</b>	Jens Eckstein
<b>Date of last notice</b>	02 July 2024
<b>Date that director ceased to be director</b>	14 November 2024

### Part 1 - Director's relevant interests in securities of which the director is the registered holder

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

#### Number & class of securities

- (1) 600,000 - Employee Share Option Plan - Options
- (2) 20,988,095 - Ordinary Fully Paid Shares
- (3) 750,000 - Restricted Stock Units (RSUs)

### Part 2 - Director's relevant interests in securities of which the director is not the registered holder

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

<b>Name of holder &amp; nature of interest</b> <i>Note: Provide details of the circumstances giving rise to the relevant interest.</i>	<b>Number &amp; class of Securities</b>
Nil	Nil

### Part 3 - Director's interests in contracts

<b>Detail of contract</b>	
---------------------------	--

+ See chapter 19 for defined terms.

**Appendix 3Z**  
**Final Director's Interest Notice**

---

<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>No. and class of securities to which interest relates</b>	

---

+ See chapter 19 for defined terms.